FDA Safety Review of Mifepristone: Evaluating Concerns and Evidence
The Food and Drug Administration (FDA) is currently evaluating the safety of the abortion pill mifepristone, as mentioned in a recent letter from Health and Human Services Secretary Robert F. Kennedy Jr. to Republican state attorneys general. Concerns have been raised by conservatives and anti-abortion groups, especially after the Biden administration expanded access to mifepristone through telehealth and mail in 2023. The majority of women who opt for pregnancy termination choose medication abortions. The FDA is reviewing the Risk Evaluation and Mitigation Strategy of the drug following inquiries from Republican attorneys general and Kennedy's request to FDA Commissioner Martin Makary to examine the latest data on mifepristone.
In a letter dated September 19, Kennedy and Makary informed the states that the FDA, under the umbrella of HHS, is conducting its own review of the evidence regarding the safety and efficacy of mifepristone, including real-world outcomes and evidence. Concerns have been raised about potential risks associated with offering mifepristone without adequate medical supervision, citing data from FDA reports between 2000 and 2012 that documented adverse events, including instances of blood loss requiring transfusions. The FDA's review is aimed at assessing the safety and effectiveness of the drug.
A study by the Ethics and Public Policy Center (EPPC) highlighted by Kennedy and lawmakers like Sen. Josh Hawley of Missouri reported that nearly 11% of women may experience serious adverse events within 45 days following a mifepristone abortion. However, other data sources suggest a much lower rate of serious complications, less than 1 in 200, according to CBS News medical contributor Dr. Celine Gounder. The EPPC study, which applies the Judeo-Christian moral tradition to public policy, has been referenced in discussions about the safety of mifepristone.
While it may be challenging for the FDA to revoke approval of mifepristone, Gounder suggested that the safety review could lead to restrictions on access to the drug, such as limiting availability through telehealth or mail, or restricting prescription authority to doctors only. Kennedy and Makary did not specify a timeline for the completion of the review but assured the states that updates would be provided as the FDA's evaluation progresses.
Advocates of access to the abortion pill emphasize its safety record, citing over 100 studies that support the safety of mifepristone. The American Civil Liberties Union (ACLU) stated that medication abortion is a common method, accounting for a significant portion of abortions in the U.S., and medical associations recognize the importance of mifepristone for both abortion and miscarriage care.
In conclusion, the FDA is conducting a safety review of the abortion pill mifepristone, prompted by concerns raised by Republican state attorneys general and Health and Human Services Secretary Robert F. Kennedy Jr. The review aims to assess the safety and efficacy of mifepristone, considering real-world outcomes and evidence. While different studies present varying perspectives on the risks associated with mifepristone, advocates stress its safety and importance in abortion and miscarriage care.